TopiVert Pharma Limited: TopiVert completes TOP1630 preclinical development
LONDON, UNITED KINGDOM -- (Marketwired) -- 05/16/16 -- TopiVert Pharma Limited TopiVert completes preclinical development with TOP1630 for dry eye disease IND to be submitted in US in H2 2016 Phase I/II study on track to commence in US in early 2017 London …